{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:26Z","timestamp":1792839746169,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sustained viral response (SVR) rates for direct\u2010acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF\/VEL\/VOX) is a potent DAA combination primarily used for the retreatment of patients who failed by DAA therapies. Here we evaluate retreatment outcomes and the effects of resistance\u2010associated substitutions (RAS) in a real\u2010world cohort, including a large number of genotype (GT)3 infected patients. 144 patients from the UK were retreated with SOF\/VEL\/VOX following virologic failure with first\u2010line DAA treatment regimens. Full\u2010length HCV genome sequencing was performed prior to retreatment with SOF\/VEL\/VOX. HCV subtypes were assigned and RAS relevant to each genotype were identified. GT1a and GT3a each made up 38% (GT1a\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a055, GT3a\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a054) of the cohort. 40% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a058) of patients had liver cirrhosis of whom 7% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a04) were decompensated, 10% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a014) had hepatocellular carcinoma (HCC) and 8% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a012) had received a liver transplant prior to retreatment. The overall retreatment SVR12 rate was 90% (129\/144). On univariate analysis, GT3 infection (50\/62; SVR\u00a0=\u00a081%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a0.009), cirrhosis (47\/58; SVR\u00a0=\u00a081%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a0.01) and prior treatment with SOF\/VEL (12\/17; SVR\u00a0=\u00a071%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a0.02) or SOF+DCV (14\/19; SVR\u00a0=\u00a074%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a0.012) were significantly associated with retreatment failure, but existence of pre\u2010retreatment RAS was not when viral genotype was taken into account. Retreatment with SOF\/VEL\/VOX is very successful for non\u2010GT3\u2010infected patients. However, for GT3\u2010infected patients, particularly those with cirrhosis and failed by initial SOF\/VEL treatment, SVR rates were significantly lower and alternative retreatment regimens should be considered.\n                  <\/jats:p>","DOI":"10.1111\/jvh.13549","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T09:02:43Z","timestamp":1621328563000},"page":"1256-1264","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Real world SOF\/VEL\/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy"],"prefix":"10.1111","volume":"28","author":[{"given":"David A.","family":"Smith","sequence":"first","affiliation":[{"name":"Nuffield Department of Medicine Peter Medawar Building for Pathogen Research University of Oxford Oxford UK"},{"name":"NIHR Oxford Biomedical Research Centre Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7186-2482","authenticated-orcid":false,"given":"Daniel","family":"Bradshaw","sequence":"additional","affiliation":[{"name":"National Infection Service Public Health England London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L","family":"Mbisa","sequence":"additional","affiliation":[{"name":"National Infection Service Public Health England London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen F.","family":"Manso","sequence":"additional","affiliation":[{"name":"National Infection Service Public Health England London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"Bibby","sequence":"additional","affiliation":[{"name":"National Infection Service Public Health England London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua B","family":"Singer","sequence":"additional","affiliation":[{"name":"MRC\u2010University of Glasgow Centre for Virus Research Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1482-0889","authenticated-orcid":false,"given":"Emma C","family":"Thomson","sequence":"additional","affiliation":[{"name":"MRC\u2010University of Glasgow Centre for Virus Research Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"da Silva Filipe","sequence":"additional","affiliation":[{"name":"MRC\u2010University of Glasgow Centre for Virus Research Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu","family":"Aranday\u2010Cortes","sequence":"additional","affiliation":[{"name":"MRC\u2010University of Glasgow Centre for Virus Research Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Azim","family":"Ansari","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine Peter Medawar Building for Pathogen Research University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Brown","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine Peter Medawar Building for Pathogen Research University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hudson","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine Peter Medawar Building for Pathogen Research University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Benselin","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre (BRC) Nottingham University Hospitals NHS Trust and the University of Nottingham Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Healy","sequence":"additional","affiliation":[{"name":"Public Health Wales Microbiology Cardiff University Hospital of Wales Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Troke","sequence":"additional","affiliation":[{"name":"Gilead Sciences Ltd London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McLauchlan","sequence":"additional","affiliation":[{"name":"MRC\u2010University of Glasgow Centre for Virus Research Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine Peter Medawar Building for Pathogen Research University of Oxford Oxford UK"},{"name":"NIHR Oxford Biomedical Research Centre Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-3168","authenticated-orcid":false,"given":"William L.","family":"Irving","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre (BRC) Nottingham University Hospitals NHS Trust and the University of Nottingham Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30343-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1000"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.032"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.06.035"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29837"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30225"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"e_1_2_9_10_1","unstructured":"American Association for the Study of Liver Diseases.Recommendations for Testing Managing and Treating Hepatitis C | HCV Guidance. American Association for the Study of Liver Diseases. Accessed December 8 2017.http:\/\/www.hcvguidelines.org\/"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613512"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13115"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.020"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.002"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw362"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00330-16"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.10.007"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2459-9"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/v11040323"},{"key":"e_1_2_9_20_1","first-page":"1","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir\/voxilaprevir for HCV NS5A\u2010inhibitor experienced patients with difficult to cure characteristics","volume":"24","author":"Papaluca T","year":"2020","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.07.023"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.12.015"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18050962"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24255"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1060"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu697"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.06.013"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.031"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.017"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13549","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13549","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T17:21:58Z","timestamp":1693329718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/jvh.13549"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13549","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.13.20211862","asserted-by":"object"}]},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"2021-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}